Discontinued — last reported Q4 '24
Business Segments · Total Assets
U.S. Pharmaceutical — Total Assets
McKesson U.S. Pharmaceutical — Total Assets increased by 12.0% to $46.81B in Q1 2024 compared to the prior quarter.
Analysis
StatementSegment
CategoryCapital Allocation
SignalContext dependent
VolatilityStable
First reportedQ4 2020
Last reportedQ4 2024May 8, 2024
Rolls up toTotal Assets
How to read this metric
An increase suggests business expansion or higher investment in working capital, while a decrease may signal divestitures or improved asset turnover efficiency.
Detailed definition
This metric represents the aggregate value of all assets, including inventory, accounts receivable, property, plant, and...
Peer comparison
Major pharmaceutical wholesalers typically report segment assets to demonstrate the scale of their distribution network and inventory management capabilities relative to their peers.
Metric ID:
mck_segment_u_s_pharmaceutical_total_assetsHistorical Data
3 periods
| Q4 '22 | Q4 '23 | Q4 '24 | |
|---|---|---|---|
| Value | $38.35B | $41.79B | $46.81B |
| QoQ Change | — | +9.0% | +12.0% |
| YoY Change | — | +9.0% | +12.0% |
Range$38.35B – $46.81B
Avg YoY Growth+10.5%
Median YoY Growth+10.5%
Current Streak2+ quarters growth
Similar Metrics at Other Companies
Frequently Asked Questions
- What is McKesson's u.s. pharmaceutical — total assets?
- McKesson (MCK) reported u.s. pharmaceutical — total assets of $46.81B in Q1 2024.
- What does u.s. pharmaceutical — total assets mean?
- The total value of all resources and assets owned and utilized by the U.S. Pharmaceutical business segment.